ProQR Therapeutics N.V.
PRQR · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.19 | 0.35 | -0.52 | -0.02 |
| FCF Yield | -6.31% | -12.38% | -4.54% | -4.45% |
| EV / EBITDA | -6.86 | -1.37 | -13.19 | -7.53 |
| Quality | ||||
| ROIC | -11.07% | -8.72% | -7.46% | -11.92% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.11 | 0.94 | 1.57 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | 50.98% | 59.81% | 70.55% | 63.08% |
| Free Cash Flow Growth | 28.21% | -68.99% | -59.53% | 8.89% |
| Safety | ||||
| Net Debt / EBITDA | 8.89 | 11.40 | 22.71 | 8.82 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 57.20 | 54.91 | 42.36 | 30.56 |